Literature DB >> 8228555

Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men.

C J Glueck1, H I Glueck, D Stroop, J Speirs, T Hamer, T Tracy.   

Abstract

To assess relationships of endogenous testosterone with fibrinolysis and coronary heart disease risk factors in 55 newly referred hyperlipidemic men, we studied the relationships of testosterone to basal fibrinolytic activity, lipids, lipoproteins, and apolipoproteins. Testosterone correlated positively with the major stimulator of fibrinolysis, tissue plasminogen activator activity (r = 0.30; p = 0.02) and correlated inversely with two independent coronary heart disease risk factors, plasminogen activator inhibitor activity, the major fibrinolysis inhibitor (r = -0.33; p = 0.01), and fibrinogen (r = -0.39; p = 0.004). Testosterone correlated inversely with plasma triglycerides (r = -0.33; p = 0.01). Stepwise multiple regression was done with fibrinolytic activities as the dependent variables, and age, Quetelet Index (relative ponderosity), apolipoprotein A-I, apolipoprotein B, triglyceride, testosterone, time of blood sampling, and lipoprotein (a) as explanatory variables. Testosterone was an inverse, independent predictor of fibrinogen (p = 0.002); 53% of the variance of fibrinogen could be accounted for by age and triglyceride level (positive; p = 0.001, p = 0.01), and by apolipoprotein A-I and testosterone (negative; p = 0.02, p = 0.002). Testosterone was an independent inverse predictor of tissue plasminogen activator antigen (p = 0.0008), with tissue plasminogen activator antigen correlating inversely with tissue plasminogen activator activity. Quetelet index and apolipoprotein B were independent negative predictors of tissue plasminogen activator activity (p = 0.02, p = 0.03); Quetelet index and triglycerides were independent positive predictors of plasminogen activator inhibitor activity (p = .0001, p = .0001) and alpha 2-antiplasmin (p = 0.0003, p = 0.009).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8228555

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  15 in total

Review 1.  Andropause. Testosterone replacement therapy for aging men.

Authors:  J Bain
Journal:  Can Fam Physician       Date:  2001-01       Impact factor: 3.275

2.  Testosterone and cardiovascular disease in men.

Authors:  Paul D Morris; Kevin S Channer
Journal:  Asian J Androl       Date:  2012-04-23       Impact factor: 3.285

3.  Sex steroids and heart rate variability in patients after myocardial infarction.

Authors:  Jerzy Krzysztof Wranicz; Marcin Rosiak; Iwona Cygankiewicz; Piotr Kula; Krzysztof Kula; Wojciech Zareba
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-04       Impact factor: 1.468

4.  Plasma adiponectin concentration in relation to severity of coronary atherosclerosis and cardiovascular risk factors in middle-aged men.

Authors:  Katarzyna Dunajska; Andrzej Milewicz; Diana Jedrzejuk; Jadwiga Szymczak; Wiktor Kuliczkowski; Piotr Salomon; Dariusz Bialy; Karol Poczatek; Przemysław Nowicki
Journal:  Endocrine       Date:  2004-12       Impact factor: 3.633

5.  Blood coagulation and fibrinolysis in male patients with hypogonadotropic hypogonadism: plasma factor V and factor X activities increase in hypogonadotropic hypogonadism.

Authors:  C Erem; M Kocak; A Hacihasanoglu; M Yilmaz
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

6.  Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer.

Authors:  M M Cherrier; S Aubin; C S Higano
Journal:  Psychooncology       Date:  2009-03       Impact factor: 3.894

7.  Short term effects of GnRH agonists on plasma fibrinolytic balance in patients with advanced prostate cancer.

Authors:  Mehmet Agirbasli; Oytun A Baykan; Ali Tekin; Feridun Sengor; Altug A Cincin; Muzaffer Demir; Douglas E Vaughan
Journal:  J Thromb Thrombolysis       Date:  2008-01-09       Impact factor: 2.300

Review 8.  Androgen deficiency as a predictor of metabolic syndrome in aging men: an opportunity for intervention?

Authors:  Dheeraj Kapoor; T Hugh Jones
Journal:  Drugs Aging       Date:  2008       Impact factor: 4.271

Review 9.  Testosterone for the aging male; current evidence and recommended practice.

Authors:  Roger D Stanworth; T Hugh Jones
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

10.  The ratio of second to fourth digit length (2D:4D) and coronary artery disease in a Han Chinese population.

Authors:  Xing-Li Wu; Ding-You Yang; Wen-Hui Chai; Ming-Lei Jin; Xing-Chun Zhou; Li Peng; Yu-Sheng Zhao
Journal:  Int J Med Sci       Date:  2013-09-10       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.